Globally, the majority of patients diagnosed with cancer present for treatment in a palliative rather than a curative therapy setting. This is true whether addressing cancer in the poorest country or the richest. While the idealistic goals of oncology are to prevent and cure cancer, the realistic aspiration is to give the patient the absolutely best outcome possible with the therapeutic tools available today. The importance of understanding the unique bidirectional interplay between nutrition and chemotherapy in attaining this goal is the basis of this chapter.
Globally, the majority of patients diagnosed with cancer present for treatment in a palliative rather than a curative therapy setting. This is true whether addressing cancer in the poorest country or the richest. While the idealistic goals of oncology are to prevent and cure cancer, the realistic aspiration is to give the patient the absolutely best outcome possible with the therapeutic tools available today. The importance of understanding the unique bidirectional interplay between nutrition and chemotherapy in attaining this goal is the basis of this chapter.
General Overview of Chemotherapy

History
Chemotherapy is the mainstay of the medical oncologist's approach. Both the terminology and the science of oncology are amazingly young [1] , despite the fact that descriptions of cancerous growths have been present since earliest recorded history. This youthfulness holds both the frustration and the promise of the field.
The historic roots of "chemotherapy" lie in the initial work of Paul Ehrlich who coined the term. Ehrlich's use of rodent models of infectious diseases to develop antibiotics influenced George Clowes at Roswell Park Memorial Institute in the early 1900s. He developed inbred rodent lines that could carry transplanted tumors used to screen potential anticancer drugs and that provided the foundation for mass screenings of potential agents.
184
The direct therapeutic application of alkylating agents in human malignancy came after an unfortunate accident of military research. Severe marrow and lymphoid hypoplasia developed in seamen with exposure to nitrogen mustard after an explosion during efforts to develop its potential war uses. This clinical observation led to the initial application of modern chemotherapeutic agents. The first such attempt was made in hematopoietic neoplasms such as Hodgkin's and lymphocytic lymphomas at the Yale Cancer Center in 1943, with publication delayed until 1946 because of the war. Excellent initial responses in hematologic malignancies appeared to hold great promise. Unfortunately the responses were invariably followed by recurrences.
It was at this point that the role of specific nutrient manipulation of tumor metabolism was introduced. Farber's observation of the accelerating effects of folic acid on leukemic cell growth in children with lymphoblastic leukemia led to the development of the use of folic acid antagonists as cancer drugs. The development of cancer chemotherapy began in earnest after this understanding of the ability of nutrient manipulation of tumor pathways to modulate replication and progression.
Great strides have been made since the possibility to cure childhood leukemias and Hodgkin's lymphoma with combination chemotherapy became available in the 1960s. Unfortunately the curious distribution of responses to chemotherapy has remained unanswered, with 90% of all drug cures occurring in 10% of cancer types.
Principles [2, 3] Methods to categorize chemotherapeutic agents vary but are generally based on either the mechanism of anticancer action or the production source of the agent. General mechanisms by which chemotherapeutic agents act to inhibit cell multiplication and tumor growth occur at several levels including macromolecule synthesis and function, cytoplasmic organization, and cell membrane synthesis and function [4] . The predominant mechanism of classic chemotherapeutic agents (not including immunotherapeutic agents and other biologic response modifiers) is based on their primary effects on macromolecular synthesis or function, with interference in either the synthesis of DNA, RNA or proteins, or with the appropriate functioning of the preformed molecule.
Work with in vivo and in vitro models has been a cornerstone of research in the development of potential chemotherapeutic agents. Such modeling is described in detail in other chapters with discussion of the strengths and weaknesses of such models. Much of the early clinical work in cancer chemotherapy was based on the kinetic modeling of drug therapy of the rodent leukemia L1210 [5, 6] . Cell kinetic studies showed it to be an exponentially growing tumor with a growth fraction of 100%, unparalleled in human cancers. The mathematic modeling of cell kill using L1210 could never be made to fit the fraction of cycling cells in curable human tumors. Chemotherapy effects more rapidly dividing cells and helps to explain the 185 sites of maximal therapeutic toxicity (gastrointestinal tract and bone marrow) as well as being part of the basis for treatment effect. However, tumor cells may demonstrate significant heterogeneity for several different parameters, including the rate of cell division. The antineoplastic effect is, therefore, significantly impacted by the fraction of the total cell population that is undergoing division.
This cellular heterogeneity serves as the basis for several of the underlying principles of oncology, including the use of combination chemotherapy which utilizes agents acting by multiple different mechanisms. Both tumor cell growth and death are dependent on several variables: cell cycle time, growth fraction, total cell population, and intrinsic death rate. Many chemotherapeutic agents are grouped according to the dependence on whether cells are in cycle (i.e., not in the resting or G 0 state) and, if they are dependent on being in cycle, whether their activity is greater when the cell is in a specific phase of the cycle. These lead to the categorization of agents as phase-and cycle-specific.
Categorization of chemotherapeutic agents aids in understanding how the drugs act mechanistically as well as synergistically. The categorization used here is a common one and is summarized in Table 1 . Full discussion of these agents is beyond the scope of this chapter and would duplicate the information found in more complete resources [2, 3] .
Alkylating agents are the oldest in use for systemic chemotherapy and include a diverse group of chemical compounds that are capable of forming molecular bonds with nucleic acids, proteins, and many molecules of low molecular weight. Either the compounds are electrophiles or they generate electrophiles in vivo to produce polarized molecules with positively charged regions. These polarized regions interact with electron-rich regions of most cellular molecules. The cytotoxic effect of the alkylating agents appears to relate primarily to the interaction between the electrophiles and DNA. Because they interact with preformed DNA, RNA, and protein, the alkylating agents are not phase-specific and at least some are cell cycle-nonspecific. Examples include nitrogen mustards, ethylenimine derivatives, alkyl sulfonates, triazine, nitrosourea, and metal salts.
Antimetabolites are a group of low molecular weight compounds that exert their effect by virtue of their structural or functional similarity to naturally occurring metabolites involved in nucleic acid synthesis. Because the cell mistakes them for the normal metabolite, they either inhibit critical enzymes involved in nucleic acid synthesis or become incorporated into the nucleic acid and produce incorrect codes. Examples include folic acid analogs, pyrimidine analogs, and purine analogs.
Natural products are grouped together not on the basis of activity but because they are all derived from natural sources. The clinically useful drugs are categorized as plant products, fermentation products of certain species of the soil fungus Streptomyces, and bacterial products. Examples include mitotic inhibitors, podophyllum derivatives, antibiotics, and enzymes. Several hormones and hormone antagonists are clinically active against cancer including steroidal estrogens, progestins, androgens, corticoids, and their synthetic derivatives and nonsteroidal synthetic compounds with steroid or steroid antagonist activity.
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The miscellaneous category of chemotherapeutic agents includes agents that do not fit into any of the above but which demonstrate antineoplastic activity. Examples include synthetic topoisomerase interactive agents, synthetic taxanes, differentiation agents, and others.
General Overview of Nutritional Oncology -History and Principles
The progressive inanition and wasting associated with advanced cancer have been appreciated since the earliest observations of malignancy. Unfortunately, until relatively recently, lack of systemic chemotherapeutic options limited any significant role of nutrition per se in the management of patients with cancer.
The greatest impetus to the development of nutritional intervention in oncology came from the nearly simultaneous development during the 1960s of potentially curative chemotherapeutic options as above and the technology development necessary for intravenous nutrition options. Parenteral nutrition is not the appropriate route of nutrient administration in the majority of cancer patients for a number of reasons. However, the availability of these two therapeutic interventions at the same time worked together to make possible a number of successes which moved the field of nutritional oncology forward.
Studley [7] initially quantitated the general prognostic implications of weight loss in 1936 in surgical patients. His findings were the basis of the commonly used categorization of weight loss of 1 10% as clinically significant for adverse outcomes including complication and death. Specification of the prognostic implications of even larger weight losses was similarly defined in the paper. In 1977, Blackburn et al. [8] defined categories of weight loss in general hospitalized patients associated with increased complications and death as outlined in Table 2 .
The most widely referenced article addressing the adverse implications of weight loss in cancer is the retrospective analysis by DeWys et al. [9] . They demonstrated the effect of weight loss at baseline on outcomes in 3,047 oncology patients undergoing chemotherapy in the Eastern Cooperative Oncology Group. The frequency of weight loss ranged from 31% for favorable non-Hodgkin's lymphomas to 87% in gastric cancer. Median survival in patients with weight loss was significantly shorter in 9 of 12 protocols compared with patients with no weight loss. Chemotherapeutic response rates were lower in the patients with weight loss. However, this was statistically significant only in patients with breast cancer. Decreasing weight was correlated with decreasing performance status except for patients with pancreatic and gastric cancer. Within performance status categories, weight loss was associated with decreased median survival. The frequency of weight loss increased with metastatic disease; however, within categories of anatomic involvement, weight loss was associated with decreased median survival. These observations emphasize the prognostic effect of weight loss, especially in patients with favorable performance status or with limited anatomic tumor involvement. The power of this independent prognostic implication of weight loss has been documented by others [10] [11] [12] [13] .
DeWys et al. [9] comment that the difference in the incidence and severity of weight loss may reflect differences in the natural history of different tumors. These data also represent the natural history of untreated weight loss on prognosis. It is possible to say this given that (1) no consistent nutritional intervention was undertaken, and (2) those patients who have baseline weight loss are those who are at highest risk for further loss of weight during chemo-and radiation therapy. The statements made by the authors concerning how poor nutrition and associated weight contribute to poor prognosis is perhaps better appreciated now than in 1980. The global and interwoven effects of malnutrition and chemotherapeutic outcomes (response and complication) were clear but unfortunately these findings have not been addressed in any standardized and proactive clinical intervention trials during the past 20 years. DeWys et al. [9] commented on the interrelation between weight loss and performance status, with disproportionate loss of muscle mass in malignancy as compared with starvation. The compromised survival of weight-losing cancer patients is potentially contributed to by increased risk for pulmonary complications, decreased immunologic reactivity and infectious susceptibility. It was also suggested that differences in response to chemotherapy by weight loss status could reflect the effect of weight loss on tumor cell kinetics. As weight loss in the host increases, the growth rate of a tumor slows. A major determinant of this slowing of tumor growth is a diversion of tumor cells from a proliferating state to a nonproliferating state, which is associated with decreased sensitivity to chemotherapy.
While the adverse prognostic effects of weight loss in cancer have been documented by others [10] [11] [12] [13] , DeWys et al. [7] demonstrated that even small amounts of weight loss (! 5% of body weight at baseline) may worsen prognosis during treatment with chemotherapy. Additionally, they strongly pointed out that the prognostic effect of weight loss was greatest in patients with more favorable prognosis -those with good performance status or limited tumor extent. Unfortunately, the lessons have not been learned nor have correctly designed studies been carried out.
The development of viable options for use of parenteral nutrition in patients with cancer in the late 1960s and early 1970s allowed survival from a nutritional death in those patients who underwent successful antineoplastic therapy. Unfortunately, over the past 30 years, the term "nutritional support" has become nearly synonymous with parenteral nutrition and, at times, enteral nutrition. The implications of using these terms interchangeably have been missed even in classic reviews on the use of nutritional support in patients with cancer [14] . Use of parenteral nutrition, while addressing the calorie and protein requirements, ignores the important role of gut nutrition. Normal human physiology is based on the supply of nutrients to the body through sequential steps of digestion, absorption into the portal system and delivery of nutrients to the liver, followed by systemic delivery. Except for protein synthesis for systemic use and release of stored glucose, the general flow of nutrients is from the gut or muscle to the liver for metabolic processing and then on to the body. Not only does parenteral nutrition simply subvert this process, it precludes the nutritional and functional support of the gastrointestinal tract.
The interaction of nutrition and immune competence is broad and goes beyond the interaction of specific nutrients and specific immune modulators (Table 3, 4). It is often forgotten, or not fully appreciated, that the largest immunologic organ of the body is the "gut-associated lymphatic tissue" [15] . This gutassociated immunologic function contributes significantly to systemic immune competence.
Within days of no enteral stimulation by food (as in bowel rest with or without parenteral nutrition and potentially in severe anorexia with poor oral intake), there is significant mucosal atrophy with decreases in villous height and number, as well as decreases in mucosal cell turnover. In addition to the appreciation of the gut's role in immune competence, there is extensive literature addressing the phenomena of bacterial and endotoxin translocation in a gut with impaired permeability. In animal models, the bacteria that are most frequently associated with translocation include Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeroginosa, Staphylococcus epidermidis, Candida albicans, and Enterococci. The practicing oncologist will recognize these as among the most common bacteria cultured from patients undergoing chemotherapy. The numerically more common anaerobic bacteria of the gut rarely translocate and in fact may be important in the prevention of translocation. Factors that promote bacterial translocation from the gut include the disruption of indigenous gastrointestinal flora leading to bacterial overgrowth, impaired immune defenses, and physical disruptions of the gut mucosal barrier [15] . While malnutrition alone does not appear to be sufficient to induce translocation, several precipitating factors frequently seen in oncology patients are synergistic. These include endotoxin, radiation therapy, cytotoxic and immunosup- Neither time course (rapidity) nor total cumulative weight change is considered in grading of toxicity.
pressive drugs, cytokines, bowel obstruction, parenteral nutrition used with concomitant morphine sulfate, broad-spectrum antibiotics (especially those aimed at anaerobic flora), biliary obstruction or lack of bile, T-cell or macrophage dysfunction, and abnormalities in secretory immunoglobulin A (S-IgA).
In addition, the presence of tumor per se may increase gut translocation via a circulating soluble factor that may inhibit macrophage function. Specifically, parenteral nutrition adversely effects several of these precipitating components of gastrointestinal immune competence. Use of parenteral nutrition has been shown to slow transit time with decreased peristalsis, precipitate mucosal atrophy in the absence of intestinal nutrients, decrease biliary and intraluminal S-IgA, impair host immune responsiveness as measured by differential neutrophil activation, lymphocyte function, chemotaxis, and macrophage function. The use of the conditionally essential amino acid, glutamine, to counteract some of these deficits of parenteral nutrition is addressed in another chapter.
Nutritional Oncology in 2000 and Beyond
It is unfortunate to have to admit that much of what we think we know about the interaction of nutrition and chemotherapy is either outdated or potentially wrong. If the model upon which many of our suppositions of intervention are based is incorrect (e.g., use of parenteral nutrition to test the hypothesis that supplying calories and protein is adequate to impact oncologic outcomes), we simply cannot make valid conclusions about the results based on the model.
Proactive and Standardized Nutritional Assessment and Intervention
Current standards for grading nutritional toxicity (i.e., weight loss associated with chemotherapy) are inconsistent with data available on the prognostic impact of weight loss and prognosis in cancer and other disease states. Table 5 summarizes the weight loss criteria used by the National Cancer Institute (USA). In general, the National Cancer Institute's grade 0-2 toxicities include side effects that 193 are expected or tolerated, with standardized interventions such as dose modification or treatment delay occurring only with grade 3-4 toxicity scores. Grade 3 weight loss is defined as loss of 1 20% while the patient is undergoing therapy. It fails to take into consideration (1) acuteness and pattern of weight loss, or (2) total cumulative loss (baseline plus treatment-related). Additionally, there is no definition of grade 4 nutritional toxicity (i.e., life-threatening) despite the fact that acute weight loss of 130-40% is associated with premature death in several disease settings.
When comparing the criterion of 20% weight loss for grade 3 toxicity with the known prognostic implications of much lesser degrees, this author feels that the Common Toxicity Criteria are critically off base, that is if we want to meet the oncologic goal specified in the introduction -to give the cancer patient absolutely the best palliation possible with the therapeutic tools available.
In order to clearly define the role of adjunctive nutritional therapy and maintenance of body composition, both within the setting of clinical trials and in dayto-day clinical practice, healthcare professionals must have access to an effective, reproducible, and easy-to-use nutritional assessment tool. The use of a standardized instrument for nutritional assessment facilitates serial evaluation of nutritional status and guides appropriate interventions [17] . The scored Patient-Generated Subjective Global Assessment of Nutritional Status (PG-SGA) provides such a tool [16, 18] .
The PG-SGA is an instrument that can be used as a screening tool or as part of a comprehensive nutritional assessment (Appendix). It has been accepted by the Oncology Practice Group of the American Dietetic Association (USA) as the standard for nutritional assessment of oncology patients [19] , and is widely used in educational programs for oncology nurses in the United States.
The PG-SGA is based on the original subjective global assessment (SGA) developed at the University of Toronto and first published in a usable format in 1987 [20] . The patient-generated format is different from the original SGA in that the patient completes the time-consuming part of the process -patient history. The broad categories of A, B, or C (well-nourished, moderately malnourished, or severely malnourished) have been deemed "too subjective" by many clinicians. The scored PG-SGA addresses these concerns and additionally gives both clinicians and patients a numerical score that can change significantly with improvement or impairment of nutritional risk factors.
These two assessment tools (SGA and PG-SGA) include prognostic components of patient history (amount and pattern of weight loss, qualitative assessment of nutritional intake, and standard performance status scales) as well as clinical history (disease, metabolic stress, and physical examination). Additionally, in the PG-SGA a specific check-off list of nutrition-impact symptoms is included which enables patients to be more forthcoming about symptoms (often not classically thought of in a nutritional context by clinicians) that adversely impact nutrient intake and quality of life.
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The one-page PG-SGA can be used by any clinician (e.g., physician, nurse, dietitian) in an inpatient, outpatient, homecare, or hospice setting. The first four boxes of the PG-SGA are filled out by the patient who provides a current history of weight change, food intake, symptoms, and functional capacity. The patient section is aimed at a sixth to eighth grade reading level. In addition to the original English version, Spanish and several other language versions are available. The clinician component of the form includes scored assessments of disease, metabolic stress, and physical examination. Additional information concerning the use of the scored PG-SGA can be obtained from the author.
Persson et al. [21] recently published outcome results using a Swedish translation of an earlier nonscored version of the PG-SGA. Eighty-seven patients with gastrointestinal and urologic tumors completed the initial four sections of the form (weight history, intake, symptoms, and functional capacity) and the remaining sections were independently completed by a physician and dietitian. Combining the patient and clinician data led to classification of the patient as well-nourished (SGA-A), moderately malnourished or suspected of being malnourished (SGA-B), or severely malnourished (SGA-C). Interobserver agreement was complete in 90% of the cases. More patients with gastrointestinal cancers than with urologic cancers were classified as SGA-B or C. Mean values of serum albumin and plasma prealbumin differed between each of the SGA classes. Univariate analyses demonstrated that all components of the instrument were significantly correlated with the SGA ranking. Multivariate logistic regression analyses showed independent contributions to the overall classification by weight loss in the previous 6 months, level of food intake, patient assessment of having problems with eating, impaired physical activity and muscle wastage on physical examination. Survival was significantly higher in patients categorized as SGA-A than in SGA-B+C (p ! 0.001). In terms of ease of use, all patients in the Swedish study were able to answer the questions and did not find them difficult according to the authors. This is consistent with the findings in the validation study of the scored PG-SGA [22] . More than 90% of 2,095 patients, including more than 200 indigent hospice patients in New York City, were able to complete the scored version of the form without difficulty. Of the 8% in this larger study who were unable to complete the form, the reasons given were: too ill (25%); language issue (3.4%); unable to read (4.7%); refused (3.4%), and other (62.8%, such as not having reading glasses).
With the data provided by the scored PG-SGA, the patient is then categorized in two ways. The first includes the addition of the point scores from each of the individual patient and clinician sections, and the second is to categorize the patient using the original version of the A, B, and C. When clinicians use the form as a standard part of the patient evaluation, the process adds approximately 1 to 3 min to the overall clinic visit. Importantly, clinicians participating in the validation study of Ottery et al. [22] estimated that it would take them more than three times as long to gain the same amount of information if not using the PG-SGA Patient education by a dietitian or nurse, with pharmacologic triage based on symptom survey (box 3, Appendix) Additive score of [4] [5] [6] [7] [8] Requires the intervention of the dietitian working in conjunction with the nurse or physician based on box 3 (Appendix) addressing nutrition-impact symptoms Additive score 69
Critical need for symptom management and/or nutritional intervention; requires interdisciplinary team discussion to address all the aspects that are impacting nutritional status (including symptoms, finances, other); requires consideration of non-oral options including enteral or parenteral nutrition as dictated by the presence of a functional gut format. They often noted that they gained information which impacts patient care that they would not normally include in their standard patient assessment. Persson et al. [21] noted that the direct patient input, especially in terms of symptoms, was quite valuable in assessment of nutritional status. Ottery et al. [22] also found that the check-off list for nutrition impact symptoms was extremely helpful in identifying nutritional impediments that are generally amenable to either pharmacologic or behavioral management. The PG-SGA has been used in the context of standardizing nutritional intervention using the SGA ranking and the nutritional risk of the specific chemotherapy or radiation therapy regimen [17, 23] . More recently, a more proactive response to nutritional risk or deficit has been defined in the validation study of Ottery et al. [22] and is summarized in Table 6 .
In addition to its usefulness in oncology clinical practice, the use of an instrument such as the scored PG-SGA is necessary in clinical trial settings in order to ensure standardization of approach and comparability of results, as in all other oncology specialties.
Bidirectional Interplay of Nutrition and Antineoplastic Therapy
Appreciation of the bidirectional interplay of nutrition and chemotherapy is critical in designing clinical trials addressing nutritional intervention studies. Chemotherapy toxicity adversely impacts nutritional intake, digestion, or absorption through one or several of the following: nausea, vomiting, constipation, diarrhea, xerostomia, dysgeusia, anorexia, delayed gastric emptying, increased intestinal transit time, malabsorption, aversions, taste and olfactory changes, fatigue.
Increasing use of multimodality therapy generally exacerbates the toxicity of each of the individual modalities in terms of increasing impediments to adequate nutrient intake, absorption, and utilization. It is also important to recognize that the incorporation of hematologic support in the form of exogenous growth factors has the potential to replace myelosuppression as the standard dose-limiting toxicity with exacerbated gastrointestinal toxicity.
In the context of supporting the nutritional status of the patient undergoing cancer therapy, adequate symptom management is truly first-line nutritional intervention. Using the format of a proactive, standardized nutritional assessment and interventional approach, the nutritional oncology service at the Fox Chase Cancer Center in Philadelphia, USA, had the following results [24] : One hundred and eighty-six consecutive patients referred to the nutrition clinic (average weight loss of 16.8% from pre-illness weight) were managed solely by oral nutrition (food and/or supplements) and excellent attention to management of nutrition impact symptoms (Box 3 of the PG-SGA, Appendix). In these patients there was a 50% success rate in getting patients to maintain or gain weight during therapy. There was also a 50% success rate in maintenance or improvement in visceral protein status assessed by serum albumin or transferrin. If data from patients with a life expectancy of ! 6 weeks were excluded, there was an approximately 80% success rate in getting patients to maintain or gain weight and to improve visceral protein status.
In contrast with the well-recognized importance of chemotherapy on intake, progressive malnutrition is associated with increased therapy toxicity including one or several of the following: (1) impaired gut-associated lymphatic tissue and systemic immune function (Table 3, 4) with increased risk of infectious complication and death; (2) abnormalities of pharmacokinetic and pharmacodynamic aspects of drug metabolism potentially contributing to any chemotherapy toxicity that is impacted by drug clearance; (3) deficiencies in micronutrients protective of nontumor cells; (4) lack of appreciation of potential dosing and timing issues in supplementing such micronutrients, and (5) loss of lean body mass with consequent delays in gastrointestinal transit, increased fatigue, and complications associated with prolonged inactivity or bed rest.
Manipulation of the nutrient milieu of the tumor-bearing host or patient has the potential to alter the effectiveness and toxicity of chemotherapeutic intervention. Certainly the use of leucovorin (5-formyl-5,6,7,8-tetrahydrofolic acid or folinic acid) is well documented in this arena. Leucovorin is indicated after highdose methotrexate (MTX) therapy. It is used to diminish MTX toxicity and to counteract the effects of impaired MTX elimination and inadvertent overdosages of folic acid antagonists. This approach is frequently referred to as "leucovorin rescue". This interaction of an antineoplastic agent and nutrient also demonstrates the potential importance of the timing of nutrient manipulation. Leucovorin in this setting is administered 24 h after MTX infusion so that the maximum therapeutic effect of MTX can be attained as well as rescue (or diminution) of toxicity to normal cells. Alternatively, specific nutrient depletion (e.g., MTX-deficient diet) has been utilized in animal models to decrease tumor growth, such as methionine deficiency. Unfortunately this type of manipulation does not trans-late well into humans due to differences in cell kinetics and the development of progressive systemic deficiency in the host (i.e., the patient).
Specific nutrients or modified nutrients have the potential to effect tumor initiation and progression, as addressed by other authors in this volume, as well as to be used as a chemotherapeutic agent. As listed in Table 1 , there are a number of agents that impact cell differentiation. Striking results have been obtained using all-trans retinoic acid in acute promyelocytic leukemia (APL) with induction of complete remission in a very high proportion of patients with APL. Other agents of this type which have shown various levels of antineoplastic activity include the use of 13-cis-retinoic acid in cutaneous T-cell lymphoma (mycosis fungoides) and in some low-grade skin cancers; 9-cis-retinoic acid in APL, kidney cancer, and AIDS-related Kaposi's sarcoma, and vitamin D 3 analogs in skin recurrences of breast cancer and cutaneous T-cell lymphoma. The use of ˆ-3 fatty acids in impacting metastatic potential and tumor-induced cachexia is addressed in other chapters.
One final arena of this bidirectional interaction of nutrition and chemotherapy that pleads for investigative research is the role of malnutrition, particularly protein deficiency, on pharmacokinetic and pharmacodynamic parameters of chemotherapeutic agents that may increase toxicity. Table 7 summarizes the variables that can determine toxicity profiles of given drugs. Full discussion of this literature is beyond the scope of this chapter, but the reader is referred to more complete resources [2, 25] .
Anabolic Competence as a Paradigm of Nutritional Intervention
A paradigm was developed in 1998 that incorporated each of the variables that act synergistically and positively to impact whole body and cellular anabolism. This concept, represented graphically in Figure 1 , has been termed "anabolic competence". Anabolic competence is defined as that functional state which optimally supports protein synthesis and lean body mass, global aspects of muscle and organ function, and immune response. This integrated approach has been demonstrated to maximize the chance of successful outcome in both research and clinical settings.
Optimizing nutritional milieu includes meeting the protein and calorie requirements matched to the metabolic or catabolic needs of the individual. Protein goals to support anabolism for the malnourished or catabolic patient are approximately 1.5 g/kg of ideal body weight/day. Optimizing the hormonal milieu can include correction of hormonal abnormalities such as hypothyroidism, insulin deficit or insulin resistance, or hypogonadal status. It can also include pharmacologic intervention such as appetite stimulation with agents such as megestrol acetate or anabolic agents such as oxandrolone. In this paradigm, exercise can include both aerobic activity, to improve gastric emptying and prevent disuse muscular atrophy, as well as progressive resistance exercise. The latter can include, but is not limited to, weights and elasticized exercise bands. Exercise This combined approach to anabolic competence is increasingly used to impact nutritional intervention strategies. While this approach has not generally been used in oncology patients, its effectiveness has been demonstrated in the elderly and in patients with HIV [26, 27] and is beginning to be addressed clinically and in early research efforts in the oncology arena.
Conclusions
Patients with cancer are at significant risk of progressive nutritional deterioration due to the cancer itself (mechanical or cytokine mediated) or due to the toxicity of the antineoplastic therapy. Progressive weight loss and malnutrition are associated with adverse prognosis, blunted or compromised responses to cancer treatment, impaired quality of life, and increased healthcare-related costs.
The inclusion of a standardized and preemptive approach to nutritional assessment and intervention is extremely important in optimizing the oncologic outcomes in both palliative and curative chemotherapy settings. The combination of the PG-SGA and the accompanying interventional recommendations represent such an approach and one which is increasingly being used on an international basis.
It is said that "the greatest obstacle to discovery is not ignorance -it is the illusion of knowledge" (Daniel J. Boorstin). In this context, the greatest obstacle to new approaches in addressing the interaction of nutrition and chemotherapy is to think we have the right answers. This chapter addresses the interplay of nutrition and chemotherapy in a way that invites a rethinking on the part of oncologists concerning what we think we know in this arena. The field of nutritional oncology is an evolving one that addresses the full spectrum of interaction of cancer and nutrition -from prevention to adjunctive and supportive therapy. The approaches included are practical, lend themselves for use in both clinical practice and clinical research settings, and allow the oncologist to attain the realistic goal of giving the patient the absolutely best outcomes with the therapeutic tools presently available.
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Discussion
Dr. Bloch: As somebody who's in the trenches doing nutrition for cancer patients, I would like to raise some issues. In New York, 70-80% of our cancer patients are on some kind of supplement, additive, or herbal agent, that they're taking of their own accord. I wonder how we can capture that in our subjective global nutritional assessment. My other concern is that so many of our patients are on these supplements, but nevertheless we often dogmatically say to them, don't use any folate, even in a general multivitamin preparation; or, if they're on certain chemotherapeutic treatments, don't use any antioxidants if you're getting any kind of therapy for 2 weeks before and during the treatment. Many of these dogmas have no basis in any kind of documentation as far as I'm aware. How do we deal with this? Do we really know what happens if somebody has folate in a multivitamin preparation, or if they're taking antioxidants as part of the overall better nutrition they're attempting?
Dr. Ottery: Those are two questions I would have brought up myself if they weren't raised from the floor. The issue of supplements or additional dietary components that are taken after someone's been diagnosed with cancer was actually raised at a press conference here in relation to Malaysian patients, so I think this is an issue across the world. The reality is that we don't have a lot of information, and the only way we're going to get it is by asking the question. Although this was not part of the original SGA (Subjective Global Assessment), I have now added questions that deal with this issue, so we know what the patients are taking in terms of over-the-counter vitamins, herbal components, and so on, including over-thecounter anabolic agents used by patients when they know they're losing muscle. We've included that as the next step, because that's the way we're going to be able to get some of those answers.
The issue about saying you can't take folate or antioxidants is, I think, rather foolish. We don't tell them they can't eat, and they're getting folate from nutrient components. So I think to say that a multivitamin that's providing somewhere between one to two times the recommended daily allowance is unrealistic because they're probably getting that in their food, if they're eating it. Some investigators are currently even looking at the impact of pharmacologic doses of antioxidants given at the time that a patient is undergoing radiation therapy. People seem to be dogmatic one way or the other -either you can't, or you must. But in fact there is a serious paucity of information. Often patients don't even want to admit to taking these things because they're concerned that their physician will be critical of them for taking other types of medicine.
Dr. Waitzberg: We've seen from published reports that parenteral and enteral nutrition in lung cancer during chemotherapy has no significant impact on survival or on toxicity reactions. In fact, some of the studies have shown adverse effects using parenteral nutrition, which has motivated the very careful approach taken by some organizations, for instance, the ASPEN guidelines. Could you comment on that, and what should be the endpoints for future studies?
Dr. Ottery: Over a period of about 5 years at Fox Chase Cancer Center in Philadelphia, we had 65 patients who were maintained on parenteral nutrition, mostly temporary, and I was very specific about who was appropriate to receive such therapy. Usually the gut wasn't working for a relatively short period of time but these people would have died from lack of functional gut after radiation treatment and surgical excision. What we found in that setting was that all the patients with a life expectancy of greater than 6-8 weeks at the start of parenteral nutrition did well. About 55% of our patients came off the total parenteral nutrition (TPN) and went onto either oral feeding or enteral nutrition. The ASPEN report found that about 40-50% of patients who were put on parenteral nutrition were dead within approximately 6 weeks or so, but the reality is that you have to choose the right people.
It is of interest that the 8% who did not respond in terms of either weight improvement or, more importantly, improvement in serum transferrin and albumin and reversal of negative nitrogen balance were the ones described by the medical oncologist as having such poor performance status that they were unsuitable for chemotherapy. In these it was a case of "Let's put them on TPN and see if we can get them better". Those are ones whom I can guarantee, from our own experience, are not going to be improved.
We were also very particular about the regimen that we were using in relation to the protein requirement: every single patient had weekly measurement of 24-hour nitrogen excretion. I don't know what a positive nitrogen balance means in a weight-losing cancer patient, but I do know what a negative nitrogen balance means. A positive nitrogen balance could indicate nitrogen going to tumor, but if they're in negative nitrogen balance, they're breaking down muscle and they're not going to be going forward.
We've got to standardize what we're doing and we have to choose the right patient. In terms of chemotherapy, if somebody has a poor performance status, or if they have certain other criteria, they don't get put on chemotherapy protocols. It should be no different for parenteral nutrition, which is a pharmacologic management. If we're doing it as a temporary component because the gut's not working, that's a little different, but we need to realize that this is a bag of chemicals being given to the patient, which are going to have an impact on what is being done to those patients in terms of the chemotherapy.
One final thing is that I've had a lot of people say, if you're giving someone extra nutrition, aren't you in fact feeding the tumor? That comes up not infrequently. The reality is that the tumor's always going to get fed, even if the person is cachectic and not having anything orally, enterally, or parenterally. There are old data, for example, in head and neck patients, that if you give parenteral nutrition you may increase the S phase. It used to be said that this meant that tumor growth was being stimulated and so we should probably not do it. The reality is that we may be able to use that to increase our cell kill, because many therapeutic interventions, whether radiation or chemotherapy, depend not on a sluggishly dividing tumor but on one that's dividing actively, or on the rapidity with which it's dividing.
Dr. Nitenberg: You are very enthusiastic and convinced, but the problem is to convince oncologists. At least in my country, and I'm sure it's the same in many others, it's very difficult to convince oncologists that what you called "supportive nutrition" could help their patients. They will say, our patients are malnourished because their tumor is aggressive, or because they have metastases, and if we don't cure the tumor, of what use will nutritional support be? How could you help me to convince my oncologists that it could be useful in some instances?
Dr. Ottery: There are a couple of ways of answering that. First, I think we can accept that malnutrition in any setting is going to have an adverse impact. Multimodality treatment is becoming part of all our protocols, so we can probably sneak nutritional therapy in as part of that treatment, in which case the medical oncologists may not think it's such an issue. Second, you can quote the work of DeWys et al. [1] from 1980, showing that in people beyond the scope of curable resection or radiation therapy at the time of diagnosis who then received chemotherapy, there was, across the board [2] , a significant impact of weight loss on outcome, survival, toxicity, and so on, even in those who had the best performance status. What was also interesting about that DeWys work is that it is really a description of the natural history of untreated malnutrition: those people who lost more than 5% before they started getting treated were the ones at higher risk down the road.
It all goes back to the issue of doing things in a standardized way, but also of addressing pharmacokinetics and pharmacodynamics any time you have a teaching session with medical oncologists or any one else who isn't convinced about nutrition. It needs to be put into the context of cellular mechanisms and what we know potentially can work. For any medical oncologists here who agree this is important, I truly apologize for comment that may seem disparaging. But it is true, many people say, "if my chemotherapy works, then the weight will 205 soon be regained". In reality that doesn't happen; they may put fat back on, but usually not lean body mass. In addition they may also die of infectious complications because we haven't addressed that issue, and the biggest issue for many of these patients is infectious complications.
Dr. Tisdale: I would like to make a couple of points. One is with regard to nutrition and tumor growth. You said that the tumor would probably be growing optimally anyway, but I rather doubt that, certainly from experimental studies that we've carried out with our animal model where the animals appear to be eating adequate amounts of food. If you give them an appetite stimulant, such as megestrol acetate, the tumor actually will grow a lot faster than in those animals not given megestrol acetate. Whether that translates into patients or not, I don't know, but there is still a possibility that the tumor is growing suboptimally under conditions of normal nutritional intake.
The other point I want to make was, we seem to have moved seamlessly between cachexia and the toxicity of chemotherapy. Although the two appear to be the same in terms of malnutrition, again I'd like to introduce a note of caution: ˆ-3 fatty acids appear to be efficacious in the treatment of cachexia associated with tumor but not with malnutrition associated with chemotherapy. So although the two effects look the same, maybe the treatments for the two are totally different.
Dr. Ottery: Tumors will behave differently depending on the nutrient milieu in which they are forming. We need answers to this question, perhaps from head and neck tumors that we can biopsy serially during nutritional manipulations. It's something that has not really been addressed and is clearly important.
I agree about the issue of cachexia and chemotherapy. These are probably not the same. Their end result may be that the patient who is malnourished because of nausea and vomiting and constipation and not eating will lose weight, and some of that will be muscle mass, especially if the patient is disproportionately failing to eat protein. The reality is that they are probably two things that act synergistically. One of the things we found using the patientgenerated subjective global assessment is that if you treat symptoms optimally you can have a great impact on weight loss. That's only addressing weight, however; we don't yet have data on body composition. These patients may be maintaining their weight but they may still be losing muscle disproportionately.
Dr. Asprer: Are there any situations in which we hold back on nutritional support? Dr. Ottery: I think there are very few occasions when I would say that it's appropriate to withhold nutrition. But if you've got an end-stage patient with a very short life expectancy, who is anorectic, who has a bowel obstruction, and who is in a hospice, it may not be appropriate to have a nasogastric tube to provide nutrients. I had a patient in whom we put a feeding tube in the neck, partly to act as a decompressor. He could have coffee down this and could socialize; he was getting nothing to eat, but he could still have some quality of life and not have a tube in his nose. When people are thirsty you make sure that they are hydrated, but most people who are in the process of dying are not hungry. In the patients you will be taking care of in the Philippines, your approach will, I'm sure, be to give them treatment that seems best to meet their needs as far as quality of life is concerned.
Dr. Argiles: I liked your concept about anabolic competence and the interactions you drew between exercise and the hormonal and nutritional milieu. Now we all know that lack of activity leads to protein degradation, and that increased exercise results in protein accretion. We also know that hormonal changes can influence catabolic and anabolic responses and you've drawn attention to what nutrition can do. Could you be brave and put percentages or relative weights in these three factors related to anabolic competence? How important are hormonal factors?
Dr. Ottery: I have absolutely no data on that. It's one of the things that we're in the process of looking at. The reality is probably that this will vary quite a bit from patient to patient, based on their baseline functional status. In relation to hormonal factors, it is possi-206 ble that low testosterone may be an important factor. Certainly we've seen in AIDS that if someone has a low testosterone level you can't make them anabolic until you take care of that. Similarly, in cachectic cancer patients, low testosterone levels may also be an issue, although confused by alterations in sex hormone-binding globulin and so on. Patients who are glucose-intolerant need treatment for that. Somebody who has a low thyroid hormone status because they've had radiation of the head and neck needs thyroid replacement. There may be times when an appetite stimulant may be appropriate. There may be other times when an anabolic agent may be appropriate.
Dr. Selvaratnam: In your own clinic, do you have any special nutritional protocols for patients with significant loss of weight, either before treatment or on treatment, and do you give them trace elements, vitamins, hormones, and so on?
Dr. Ottery: In general I do make certain that I define for the patient what their protein requirements are. I truly believe that's a very major issue. I don't necessarily try to make them achieve their theoretically optimal energy intake because that tends to take care of itself if one is meeting the protein goals. If somebody wants direction on multivitamins, my attitude is that they are very appropriate for any patient who's undergoing therapy, but they should be given as balanced multiple vitamins, not an excess of any individual vitamin such as only antioxidants, etc. In general I sit down and work with the individual patient to see if they have any nutrition impediments, what things they like, what things they think they can take, and work from that standpoint.
